www.bewet.fora.pl

Romer687vn

/>
Women's Reproductive Disorders Therapeutics 2008-2018
Women's Reproductive Disorders Therapeutics
It predicts that there is great potential for the womens reproductive disorders therapeutics market from present onwards, as this new report Womens Reproductive Disorders Therapeutics, 2008-2018 shows.
Oral Contraceptive Market
The systemic hormonal contraceptive market is currently a $7bn market, with hormonal oral contraceptives dominating the market for many years. The oral pills are increasingly facing competition from other routes of delivery. With patent expiration, several companies have begun manufacturing generic products. Hormonal contraceptives for women have become the benchmark for the safety and effectiveness of birth control methods.
Although hormonal contraceptives are already a very mature market [link widoczny dla zalogowanych], believes that there is still room for further growth. In addition, modern basic research has identified some completely new approaches for the contraceptives of the future. Hormonal oral contraceptives will continue to play an important role in birth control from 2008 to 2018.
Lifecycle Management and Product Line Extension
The hormonal oral contraceptive market is undergoing both lifecycle management and product line extension of existing products in the market. There are progestin-only preparations and combined preparations containing an oestrogen and a progestin. Bayer Schering is developing a pill containing various forms of progestin. Clinical studies show that the new drospirenone pill has an apparent therapeutic effect on premenstrual dysphoria - a particularly severe form of the premenstrual syndrome (PMS) [link widoczny dla zalogowanych], as well as on acne. Pills are increasingly being developed with reduced oestrogen dosages. Evaluates the prospects for extended or continuous administration of oral contraceptives. It is becoming popular for the treatment of endometriosis, dysmenorrhoea and menstrual-associated symptoms.
Menopause and Hormone Replacement Therapy
HRT has been the subject of considerable discussion recently. In light of recent and current studies, provides comprehensive market information on HRT market prospects from 2008 to 2018.
Womens Reproductive Disorders Therapeutics, 2008-2018 examines that market critically, through comprehensive primary and secondary research. In addition to consultation with industry opinion, this research involved a detailed study of policy documents, industrial reports and relevant news. Importantly, also applied techniques such as financial forecasting, SWOT analyses and qualitative projections. The result is a comprehensive market-based study with detailed financial analyses and informed opinion on the future of the womens reproductive health market.
In particular, our new Womens Reproductive Disorders Therapeutics, 2008-2018 report concentrates on the following essential aspects of that market:
Overview of the womens reproductive therapies market
Key industrial players in the global womens reproductive therapies market
Forecasts of global market from 2008-2018, including forecasts of the leading therapeutic agents in this market area
Forecasts for therapies in the seven leading pharmaceutical markets
Drivers and opportunities in the global womens reproductive therapies market
Restraints and threats in the global womens reproductive therapies market
Primary research, with full interview transcripts
Coverage of pipeline developments, with discussion of trends from the present onwards
Why You Should Buy This Report
In Womens Reproductive Disorders Therapeutics [link widoczny dla zalogowanych], 2008-2018 you will receive the following essential information for understanding the womens reproductive disorders therapeutics market and industry:
The value of the womens reproductive disorders therapeutics market and its principal market segments from 2008 to 2018